Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 19/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.68 |
| ▸ | PLK3 | Q9H4B4 | 7/20 | 0.61 |
| ▸ | NEK2 | P51955 | 3/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.61 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.61 |
| ▸ | PIM1 | P11309 | 2/20 | 0.61 |
| ▸ | KDR | P35968 | 2/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3250850 | 1.00 | PLK1 (0.68) | PLK1CYP3A4CYP2C9PLK3NEK2 | |
| SCHEMBL13440213 | 0.92 | PLK1 (0.68) | PLK1CYP3A4CYP2C9PLK3NEK2 | |
| SCHEMBL3250936 | 0.92 | PLK1 (0.68) | PLK1CYP3A4CYP2C9PLK3NEK2 | |
| SCHEMBL3254808 | 0.92 | PLK1 (0.65) | PLK1CYP3A4CYP2C9PLK3 | |
| SCHEMBL3264162 | 0.92 | PLK1 (0.65) | PLK1CYP3A4CYP2C9PLK3 | |
| SCHEMBL3257786 | 0.91 | PLK1 (0.62) | PLK1CYP3A4CYP2C9PLK3NEK2 | |
| SCHEMBL3254834 | 0.90 | PLK1 (0.66) | PLK1CYP3A4CYP2C9PLK3NEK2 | |
| SCHEMBL13440215 | 0.90 | PLK1 (0.66) | PLK1CYP3A4CYP2C9PLK3NEK2 | |
| SCHEMBL3616134 | 0.90 | PLK1 (0.59) | PLK1CYP3A4CYP2C9PLK3NEK2 | |
| SCHEMBL3251854 | 0.90 | PLK1 (0.73) | PLK1CYP3A4CYP2C9PLK3NEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009151914-A1 | METHODS FOR TREATING NEOPLASMS WITH A COMBINATION OF A PLK INHIBITOR AND RETINOID | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |